Literature DB >> 10920610

Relapses in multibacillary leprosy patients: effect of length of therapy.

B K Girdhar1, A Girdhar, A Kumar.   

Abstract

Two groups of MB leprosy patients, one treated to the point of smear negativity (TSN) and the other given therapy for fixed duration (24 doses of WHO MB regimen) (FDT), were compared for relapse rates during treatment and in the post-treatment period. During the follow-up of 980.2 person years in 260 patients treated with FDT, 20 relapses (2.04/100 patient years) were observed. In the other group of 301 patients, who received therapy till smear negativity, 12 relapses in 1085.46 person years (1.10/100 patient years) occurred. Comparison of survival rates (without relapse) has shown that although there is no difference up to 4 years, the risk of relapse was significantly higher on longer follow-up in the FDT group. In addition, when patients were compared on the basis of initial bacterial load, it was found that the relapse rates in patients with BI > or = 4 was significantly higher (P < 0.01) in the FDT group as compared to those receiving treatment till the point of smear negativity (4.29 versus 1.27/100 patient years). All the relapsed patients responded to retreatment with the same drug combination, indicating that the exacerbation in their condition was because of insufficient treatment. It is suggested that to prevent or reduce relapses, treatment where feasible would be continued till smear negativity, at least in patients with high BI.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10920610     DOI: 10.5935/0305-7518.20000017

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  21 in total

Review 1.  Leprosy elimination-a virtual phenomenon or a reality?

Authors:  Diana N J Lockwood
Journal:  BMJ       Date:  2002-06-22

2.  Treatment of leprosy.

Authors:  Diana N J Lockwood; Bhushan Kumar
Journal:  BMJ       Date:  2004-06-19

3.  Reactions following completion of 1 and 2 year multidrug therapy (MDT).

Authors:  Ma Victoria F Balagon; Robert H Gelber; Rodolfo M Abalos; Roland V Cellona
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

Review 4.  Leprosy.

Authors:  W Cairns S Smith; Paul Saunderson
Journal:  BMJ Clin Evid       Date:  2010-06-28

Review 5.  Advances and hurdles on the way toward a leprosy vaccine.

Authors:  Malcolm S Duthie; Thomas P Gillis; Steven G Reed
Journal:  Hum Vaccin       Date:  2011-11-01

Review 6.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 7.  Leprosy.

Authors:  Diana Nj Lockwood
Journal:  BMJ Clin Evid       Date:  2007-04-01

8.  Powerful bactericidal activity of moxifloxacin in human leprosy.

Authors:  Fe Eleanor F Pardillo; Jasmin Burgos; Tranquilino T Fajardo; Eduardo Dela Cruz; Rodolfo M Abalos; Rose Maria D Paredes; Cora Evelyn S Andaya; Robert H Gelber
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

9.  Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear.

Authors:  Malcolm S Duthie; Stephen T Reece; Ramanuj Lahiri; Wakako Goto; Vanitha S Raman; Juliette Kaplan; Greg C Ireton; Sylvie Bertholet; Thomas P Gillis; James L Krahenbuhl; Steven G Reed
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

10.  Alternate Anti-Leprosy Regimen for Multidrug Therapy Refractory Leprosy: A Retrospective Study from a Tertiary Care Center in North India.

Authors:  Tarun Narang; Anuradha Bishnoi; Sunil Dogra; Uma Nahar Saikia
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.